Keros Therapeutics (KROS) delivered earnings and revenue surprises of 36,300% and 149.64%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on ...

Warren Buffett says that if he were to start again, he’d look for old-fashioned value stocks. Stephen Wright thinks there’s an unusual one on offer. The post Why I’m considering considering breaking ...

Keros Therapeutics’ KROS shares jumped 18.5% yesterday following an announcement that it is exploring strategic options, including a potential sale of the business. To aid the decision process ...

$KROS insiders have traded $KROS stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales. Here’s a ...

Kairos Pharma (NYSE American: KAPA) , announced it will present new data on KROS 101, a small molecule GITR ligand agonist, at the 2025 American Soci ...

The Golden Eagles (34-13 overall, 17-6 Sun Belt) won their eighth-straight contest as they tossed their third shutout of the ...

Shares of Keros Therapeutics (NASDAQ:KROS) added ~22% in the premarket on Thursday after the biotech commenced a review process to evaluate different strategic options, including a potential sale ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price target of $25.00. The company’s shares closed ...

The Golden Eagles (32-13) won for the sixth consecutive game as they ended their non-conference schedule with a 17-7 mark.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...